Matthew Oberley, Chief Clinical Officer at Caris Life Sciences, shared a post by Caris Life Sciences on LinkedIn:
“New publication headed by Mark Evans and Hassan Ghani along with excellent collaborators highlights an under-recognized issue in Lung Squamous Cell Carcinoma (SCC) – namely a small but clinically significant percentage of SCC are diagnosed and treated as an early stage primary lung cancer when they are actually metastatic SCC from the skin, head and neck, or anogenital regions and represent stage IV disease.
In our new JAMA Network Open study, we found that 3.1% of cancers submitted for molecular profiling as primary lung were actually metastatic from other sites!
For our tissue profiling test, MI Cancer Seek, we have validated virus (HPV, EBV, MCV, HHV8) detection and COSMIC UV and smoking signature detection and report clinically when present. We used this information in concert with selected diagnostic IHC to conclusively demonstrate origin outside of the lung in those 3.1% of cases.
This study highlights the clinical utility of Exome and Transcriptome sequencing coupled with AI-enabled tissue of origin tools such as GPSai to ensure patients are getting the correct diagnosis – in addition to identifying appropriate therapy. Congrats to all the authors!”
Title: An AI Approach to Differentiating Lung Squamous Cell Carcinoma From Metastases of Other Origins
Authors: Mark G. Evans, Jennifer R. Ribeiro, Todd Maney, Anthony Helmstetter, Jennifer Johnson, Anthony N. Karnezis, Casey Bales, George W. Sledge, David Spetzler, Ari Vanderwalde, Matthew Oberley, Balazs Halmos, Hossein Borghaei, Farah Abdulla, David Bryant, Fred R. Hirsch, Hassan Ghani
Read the Full Article.
Other articles featuring Matthew Oberley on OncoDaily.